Size-reduced fexuprazan 20 mg demonstrated the optimal bioavailability and bioequivalence with the reference formulation.

Yang, A-Young; Yoo, Hyounggyoon; Shin, Wonsuk; Lee, Yil-Seob; Lee, Hyejung; Kim, Sung-Eun; Kim, Anhye

Yang, A-Young; Yoo, Hyounggyoon; Shin, Wonsuk; Lee, Yil-Seob; Lee, Hyejung; Kim, Sung-Eun; Kim, Anhye.

Afiliación

Yang AY; Department of Clinical Pharmacology and Therapeutics, CHA Bundang Medical Center, CHA University, Seongnam 13496, Korea.
Yoo H; Clinical Trial Center, CHA Bundang Medical Center, CHA University, Seongnam 13520, Korea.
Shin W; Department of Clinical Pharmacology and Therapeutics, CHA Bundang Medical Center, CHA University, Seongnam 13496, Korea.
Lee YS; Clinical Trial Center, CHA Bundang Medical Center, CHA University, Seongnam 13520, Korea.
Lee H; Department of Clinical Pharmacology and Therapeutics, CHA Bundang Medical Center, CHA University, Seongnam 13496, Korea.
Kim SE; Clinical Trial Center, CHA Bundang Medical Center, CHA University, Seongnam 13520, Korea.
Kim A; Department of Clinical Pharmacology and Therapeutics, CHA Bundang Medical Center, CHA University, Seongnam 13496, Korea.

Transl Clin Pharmacol ; 31(1): 40-48, 2023 Mar.

Article en En | MEDLINE | ID: mdl-37034124

Palabras clave

Bioequivalence; Gastritis; Gastroesophageal Reflux; Pharmacokinetics; Tablets

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Transl Clin Pharmacol Año: 2023 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google